Apotex
As of the edition of 20 October 2026, Apotex runs 10 drugs, 10 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Apotex was renamed in 1997.
- APOTEX CORP: renamed in 1997
Drugs by status
| Status | Count |
|---|---|
| Marketed | 10 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Docetaxel anhydrous | none listed | 0 |
| Melphalan | none listed | 0 |
| Ibuprofen | none listed | 11 |
| Acetylcysteine | none listed | 0 |
| Bendamustine | Ends 2029 (patent) | 0 |
| Paroxetine | none listed | 1 |
| Trabectedin | none listed | 0 |
| Granisetron | none listed | 2 |
| Conivaptan | none listed | 0 |
| Telavancin | Ends 2027 (patent) | 0 |
A route B row is one company at one target.